ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Drug dosing for treatment of drug-susceptible tuberculosis (rifapentine-moxifloxacin-based regimen) in patients ≥12 years

Drug dosing for treatment of drug-susceptible tuberculosis (rifapentine-moxifloxacin-based regimen) in patients ≥12 years
Drug Preparations Daily dose
(administered as a single dose)
Isoniazid* Oral:
  • Tablet: 100 mg, 300 mg
  • Oral solution: 50 mg/5 mL
IM, IV:
  • Solution for injection: 100 mg/mL
 300 mg
Rifapentine Oral:
  • Tablet: 150 mg
 1.2 g
Moxifloxacin Oral:
  • Tablet: 400 mg
IV:
  • Solution for injection: 400 mg/250 mL
 400 mg
Pyrazinamide Oral:
  • Tablet: 500 mg
 Dosing based on patient weight:
  • ≥40 to 55 kg: 1 g
  • ≥55 to 75 kg: 1.5 g
  • >75 kg: 2 g
  • The regimen summarized in this table is intended for patients with age ≥12 years, weight ≥40 kg, and CrCl ≥30 mL/min.
  • Antituberculous agents are used in multidrug combination regimens. The shortened 4-month regimen consists of an intensive phase (8 weeks of rifapentine, isoniazid, pyrazinamide, and moxifloxacin administered once daily), followed by a continuation phase (9 weeks of rifapentine, isoniazid, and moxifloxacin administered once daily). Refer to the UpToDate clinical topic for discussion.

IM: intramuscular; IV: intravenous; CrCl: creatinine clearance.

* Pyridoxine (vitamin B6) 25 to 50 mg/day is given with isoniazid to individuals at risk for neuropathy (eg, pregnant women, individuals with HIV infection, diabetes, alcoholism, malnutrition, chronic renal failure, or advanced age). For patients with peripheral neuropathy, experts recommend increasing pyridoxine dose to 100 mg/day.

¶ Based on actual body weight[1]. Some experts dose based on estimated lean body weight[2]. A calculator for estimating lean body weight is available separately in UpToDate.
Data from:
  1. Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med 2021; 384:1705.
  2. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016; 63:e147.
Graphic 131747 Version 3.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟